Skip to main content

Advertisement

SpringerLink
Log in

EuroQol (EQ-5D) health utility scores for patients with migraine

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity.

Methods

We examined data for 330 20–65-year-old adults, in good physical health, who had 1–6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods.

Results

The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654).

Conclusions

Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache, 41(7), 646–657.

    Article  PubMed  CAS  Google Scholar 

  2. Linde, M. (2006). Migraine: A review and future directions for treatment. Acta Neurologica Scandinavica, 114(2), 71–83.

    Article  PubMed  CAS  Google Scholar 

  3. Brown, J. S., Neumann, P. J., Papadopoulos, G., Ruoff, G., Diamond, M., & Menzin, J. (2008). Migraine frequency and health utilities: Findings from a multisite survey. Value Health, 11(2), 315–321.

    Article  PubMed  Google Scholar 

  4. Flanagan, W., McIntosh, C. N., Le Petit, C., & Berthelot, J. M. (2006). Deriving utility scores for co-morbid conditions: A test of the multiplicative model for combining individual condition scores. Population Health Metrics, 4, 13.

    Article  PubMed  Google Scholar 

  5. Fryback, D. G., Dasbach, E. J., Klein, R., et al. (1993). The Beaver Dam health outcomes study: Initial catalog of health-state quality factors. Medical Decision Making, 13(2), 89–102.

    Article  PubMed  CAS  Google Scholar 

  6. Ko, Y., & Coons, S. J. (2006). Self-reported chronic conditions and EQ-5D index scores in the US adult population. Current Medical Research and Opinion, 22(10), 2065–2071.

    Article  PubMed  Google Scholar 

  7. Kopec, J. A., Schultz, S. E., Goel, V., & Ivan, W. J. (2001). Can the health utilities index measure change? Medical Care, 39(6), 562–574.

    Article  PubMed  CAS  Google Scholar 

  8. Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2009). Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care, 47(1), 53–60.

    Article  PubMed  CAS  Google Scholar 

  9. Mittmann, N., Trakas, K., Risebrough, N., & Liu, B. A. (1999). Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics, 15(4), 369–376.

    Article  PubMed  CAS  Google Scholar 

  10. Mo, F., Choi, B. C., Li, F. C., & Merrick, J. (2004). Using Health Utility Index (HUI) for measuring the impact on health-related quality of Life (HRQL) among individuals with chronic diseases. Scientific World Journal, 4, 746–757.

    PubMed  Google Scholar 

  11. Saarni, S. I., Harkanen, T., Sintonen, H., et al. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Quality of Life Research, 15(8), 1403–1414.

    Article  PubMed  Google Scholar 

  12. Sullivan, P. W., & Ghushchyan, V. (2006). Preference-based EQ-5D index scores for chronic conditions in the United States. Medical Decision Making, 26(4), 410–420.

    Article  PubMed  Google Scholar 

  13. Wells, K. B., & Sherbourne, C. D. (1999). Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Archives of General Psychiatry, 56(10), 897–904.

    Article  PubMed  CAS  Google Scholar 

  14. Ho, T. W., Mannix, L. K., Fan, X., et al. (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology, 70(16), 1304–1312.

    Article  PubMed  CAS  Google Scholar 

  15. (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1), 9–160.

  16. Lines, C. R., Vandormael, K., & Malbecq, W. (2001). A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain, 93(2), 185–190.

    Article  PubMed  CAS  Google Scholar 

  17. Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.

    Article  PubMed  Google Scholar 

  18. Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.

    Article  PubMed  Google Scholar 

  19. Ekstrom, W., Nemeth, G., Samnegard, E., Dalen, N., & Tidermark, J. (2009). Quality of life after a subtrochanteric fracture: A prospective cohort study on 87 elderly patients. Injury, 40(4), 371–376.

    Article  PubMed  Google Scholar 

  20. Ekstrom, W., Miedel, R., Ponzer, S., Hedstrom, M., Samnegard, E., & Tidermark, J. (2009). Quality of life after a stable trochanteric fracture—a prospective cohort study on 148 patients. Journal of Orthopaedic Trauma, 23(1), 39–44.

    Article  PubMed  Google Scholar 

  21. Slatkowsky-Christensen, B., Mowinckel, P., Loge, J. H., & Kvien, T. K. (2007). Health-related quality of life in women with symptomatic hand osteoarthritis: A comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis and Rheumatism, 57(8), 1404–1409.

    Article  PubMed  Google Scholar 

  22. Lipton, R. B., Diamond, S., Reed, M., Diamond, M. L., & Stewart, W. F. (2001). Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache, 41(7), 638–645.

    Article  PubMed  CAS  Google Scholar 

  23. Johnson, J. A., Luo, N., Shaw, J. W., Kind, P., & Coons, S. J. (2005). Valuations of EQ-5D health states: Are the United States and United Kingdom different? Medical Care, 43(3), 221–228.

    Article  PubMed  Google Scholar 

  24. Brandes, J. L. (2008). The migraine cycle: Patient burden of migraine during and between migraine attacks. Headache, 48(3), 430–441.

    Article  PubMed  Google Scholar 

  25. Barbanti, P., Fabbrini, G., Aurilia, C., Vanacore, N., & Cruccu, G. (2007). A case-control study on excessive daytime sleepiness in episodic migraine. Cephalalgia, 27(10), 1115–1119.

    Article  PubMed  CAS  Google Scholar 

  26. Stronks, D. L., Tulen, J. H., Bussmann, J. B., Mulder, L. J., & Passchier, J. (2004). Interictal daily functioning in migraine. Cephalalgia, 24(4), 271–279.

    Article  PubMed  CAS  Google Scholar 

  27. Dahlof, C. G., & Dimenas, E. (1995). Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia, 15(1), 31–36.

    Article  PubMed  CAS  Google Scholar 

  28. Dahlof, C., Loder, E., Diamond, M., Rupnow, M., Papadopoulos, G., & Mao, L. (2007). The impact of migraine prevention on daily activities: A longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes, 5, 56.

    Article  PubMed  Google Scholar 

  29. Diamond, M., Dahlof, C., Papadopoulos, G., Neto, W., & Wu, S. C. (2005). Topiramate improves health-related quality of life when used to prevent migraine. Headache, 45(8), 1023–1030.

    Article  PubMed  Google Scholar 

  30. Diener, H. C., Agosti, R., Allais, G., et al. (2007). Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurology, 6(12), 1054–1062.

    Article  PubMed  CAS  Google Scholar 

  31. Diener, H. C., Bussone, G., Van Oene, J. C., Lahaye, M., Schwalen, S., & Goadsby, P. J. (2007). Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia, 27(7), 814–823.

    Article  PubMed  Google Scholar 

  32. Dodick, D. W., Silberstein, S., Saper, J., et al. (2007). The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache, 47(10), 1398–1408.

    Article  PubMed  Google Scholar 

  33. Schrader, H., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2001). Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ, 322(7277), 19–22.

    Article  PubMed  CAS  Google Scholar 

  34. Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003). Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA, 289(1), 65–69.

    Article  PubMed  CAS  Google Scholar 

  35. Attema, A. E., & Brouwer, W. B. (2010). On the (not so) constant proportional trade-off in TTO. Quality of Life Research, 19(4), 489–497.

    Article  PubMed  Google Scholar 

  36. Stalmeier, P. F., Lamers, L. M., Busschbach, J. J., & Krabbe, P. F. (2007). On the assessment of preferences for health and duration: Maximal endurable time and better than dead preferences. Medical Care, 45(9), 835–841.

    Article  PubMed  Google Scholar 

  37. Wright, D. R., Wittenberg, E., Swan, J. S., Miksad, R. A., & Prosser, L. A. (2009). Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics, 27(9), 713–723.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Merck Research Laboratories, where the principal author is currently employed.

Author information

Authors and Affiliations

  1. Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA

    Ruifeng Xu & Ralph P. Insinga

  2. Global Outcomes Research & Reimbursement, Global Human Health, Merck & Co., Inc., Whitehouse Station, NJ, USA

    Wendy Golden & X. Henry Hu

  3. Merck & Co., Inc., UG1C-60, P.O. Box 1000, North Wales, PA, 19454-1099, USA

    Ruifeng Xu

Authors
  1. Ruifeng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph P. Insinga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy Golden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X. Henry Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruifeng Xu.

Appendix

Appendix

See Tables 5, 6, 7, 8, 9.

Table 5 EQ-5D mobility ratings at baseline vs. 24 h post-dose
Full size table
Table 6 EQ-5D self-care ratings at baseline vs. 24 h post-dose
Full size table
Table 7 EQ-5D usual activities ratings at baseline vs. 24 h post-dose
Full size table
Table 8 EQ-5D pain/discomfort ratings at baseline vs. 24 h post-dose
Full size table
Table 9 EQ-5D anxiety/depression ratings at baseline vs. 24 h post-dose
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, R., Insinga, R.P., Golden, W. et al. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res 20, 601–608 (2011). https://doi.org/10.1007/s11136-010-9783-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-010-9783-5

Keywords

Search

Navigation